Asunto(s)
Síndrome de Inmunodeficiencia con Hiper-IgM/diagnóstico , Poliposis Intestinal/diagnóstico , Ganglios Linfáticos Agregados/patología , Adulto , Linfocitos B/inmunología , Linfocitos B/metabolismo , Biomarcadores , Biopsia , Colonoscopía , Diagnóstico Diferencial , Susceptibilidad a Enfermedades , Centro Germinal/inmunología , Centro Germinal/metabolismo , Centro Germinal/patología , Humanos , Síndrome de Inmunodeficiencia con Hiper-IgM/etiología , Cambio de Clase de Inmunoglobulina/genética , Inmunoglobulina M/sangre , Inmunoglobulina M/genética , Inmunoglobulina M/inmunología , Inmunohistoquímica , Poliposis Intestinal/etiología , Masculino , Mutación , Evaluación de SíntomasRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Adulto , Síndrome de Inmunodeficiencia con Hiper-IgM/inmunología , Pólipos Intestinales/inmunología , Citidina Desaminasa/inmunología , Citometría de Flujo/métodos , Endoscopía Gastrointestinal/métodosRESUMEN
BACKGROUND: T-helper (Th)-17 lymphocytes and neutrophils are the main sources of the proinflammatory cytokines involved in the pathogenesis of hidradenitis suppurativa (HS). OBJECTIVES: This study aims to evaluate the improvement of the inflammatory serum markers (ISM) levels in patients with moderate-to-severe HS who receive adalimumab. METHODS: Nineteen moderate-to-severe HS patients were prospectively recruited. Each of the patients received 40â¯mg of adalimumab weekly. The ISM levels and modified Hidradenitis Suppurativa Score (mHSS) scores were assessed at baseline and at week 36. Nineteen healthy volunteers (HC) constituted the control group. RESULTS: Before adalimumab treatment, the HS patients showed significantly increased levels of interleukin (IL)-6, IL-8, IL-10, IL-17A, soluble TNF receptor II (sTNF-RII), and C-reactive protein (CRP) as well as an increased erythrocyte sedimentation rate (ESR) (all Pâ¯<â¯.01). At week 36, the circulating levels of IL-1ß, IL-6, IL-8, IL-10, IL-17A, soluble TNF receptor I (sTNF-RI), sTNF-RII, and CRP, as well as the ESR (all Pâ¯<â¯.05), decreased significantly in the HS patients who received adalimumab. The decrease in levels of IL-6 (râ¯=â¯0.65, Pâ¯=â¯.003), IL-8 (râ¯=â¯0.52, Pâ¯=â¯.024), sTNF-RI (râ¯=â¯0.55, Pâ¯=â¯.015), and CRP (râ¯=â¯0.47, Pâ¯<â¯.040) and the ESR (râ¯=â¯0.60, Pâ¯<â¯.006) were significantly well correlated with clinical improvements according to the mHSS. CONCLUSIONS: Adalimumab improves the ISM-based systemic inflammatory burden in patients with moderate-to-severe HS. IL-6, IL-8, sTNF-RI and CRP and the ESR may serve as novel biomarkers for a therapeutic response.
Asunto(s)
Adalimumab/administración & dosificación , Citocinas , Hidradenitis Supurativa , Neutrófilos , Células Th17 , Adulto , Citocinas/sangre , Citocinas/inmunología , Femenino , Hidradenitis Supurativa/sangre , Hidradenitis Supurativa/tratamiento farmacológico , Hidradenitis Supurativa/inmunología , Hidradenitis Supurativa/patología , Humanos , Masculino , Persona de Mediana Edad , Neutrófilos/inmunología , Neutrófilos/metabolismo , Neutrófilos/patología , Células Th17/inmunología , Células Th17/metabolismo , Células Th17/patologíaRESUMEN
OBJECTIVES: To assess inflammatory serum markers including serum proinflammatory cytokines, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) according to the clinical inflammatory activity of patients with hidradenitis suppurativa (HS). PATIENTS AND METHODS: Seventy-four patients with HS were studied based on the Hidradenitis Suppurativa-Physician Global Assessment (HS-PGA) score and Hurley staging system. Proinflammatory cytokines were measured using a multiplex cytokine assay. Twenty-two healthy volunteers were recruited. RESULTS: Serum interleukin- (IL-) 6, IL-23, soluble tumour necrosis factor alpha (TNF-α) receptor I (sTNF-RI), CRP, and ESR were different in the patients with HS compared with those in the healthy controls (P < 0.05). The levels of IL-1ß, IL-6, IL-8, IL-10, IL-12p70, IL-17A, sTNF-RII, CRP, and ESR were significantly elevated according to inflammatory activity based on HS-PGA scores (r > 0.25, P < 0.05). The levels of IL-6 (r = 0.53, P < 0.001), CRP (r = 0.54, P < 0.001), and ESR (r = 0.60, P < 0.001) were especially well correlated with clinical inflammatory activity based on HS-PGA scores. The levels of IL-6, IL-8, sTNF-RI, sTNF-RII, CRP, and ESR were significantly elevated according to Hurley staging system. CONCLUSIONS: Serum proinflammatory cytokines, CRP, and ESR are increased in relation to the clinical inflammatory activity of patients with HS compared with healthy controls. Serum IL-6, CRP, and ESR are effective biomarkers for evaluating the severity of HS.